Get started
Work

Table 2 from Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma

Year: 2025
Type: other
Abstract: Most frequently reported AEs in >15% of patients with CS receiving ivosidenib.
DOI: 10.1158/1078-0432.29221826
Authors: William D. Tap, Gregory M. Cote, Howard Burris, Lia Gore, Anthony Elias, Murali Beeram, Anthony P. Conley, Diego A. Gianolio, Zhe Qu, Susan Pandya, Jonathan C. Trent
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4411003531
Cites:
Cited by:
Related to: 10